Studies on the ratio of equipotent oral and subcutaneous doses in man of prifinium bromide, a new synthetic spasmolytic.
D000328:Adult; D001285:Atropine / Q000008:administration & dosage*; D001535:Benactyzine / Q000008:administration & dosage*; D001681:Biological Assay; D001965:Bromides / Q000008:administration & dosage*; D002855:Chromatography, Thin Layer; D003124:Colorimetry; D003864:Depression, Chemical; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000494:pharmacology*; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage* / Q000378:metabolism / Q000652:urine; D012469:Salivary Glands / Q000378:metabolism; D012472:Salivation / Q000187:drug effects*; D012601:Scopolamine / Q000008:administration & dosage*; D013268:Stimulation, Chemical; D013431:Sulfates / Q000008:administration & dosage*; D013997:Time Factors
D001965:Bromides; D010276:Parasympatholytics; D000644:Quaternary Ammonium Compounds; D013431:Sulfates; D001535:Benactyzine; D001285:Atropine; D012601:Scopolamine